Patrick J. Haley Sells 5,560 Shares of Exelixis, Inc. (EXEL) Stock

Share on StockTwits

Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 5,560 shares of the company’s stock in a transaction on Monday, January 7th. The stock was sold at an average price of $21.51, for a total value of $119,595.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Patrick J. Haley also recently made the following trade(s):

  • On Wednesday, January 9th, Patrick J. Haley sold 1,560 shares of Exelixis stock. The shares were sold at an average price of $23.50, for a total value of $36,660.00.
  • On Wednesday, January 9th, Patrick J. Haley sold 9,120 shares of Exelixis stock. The shares were sold at an average price of $22.18, for a total value of $202,281.60.
  • On Thursday, January 3rd, Patrick J. Haley sold 8,000 shares of Exelixis stock. The shares were sold at an average price of $19.95, for a total value of $159,600.00.
  • On Wednesday, November 7th, Patrick J. Haley sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $17.32, for a total value of $346,400.00.

NASDAQ EXEL opened at $24.07 on Friday. The firm has a market capitalization of $7.08 billion, a P/E ratio of 47.20, a P/E/G ratio of 1.46 and a beta of 2.09. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $31.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.54.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.22. The business had revenue of $225.40 million during the quarter, compared to the consensus estimate of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. Exelixis’s quarterly revenue was up 47.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 earnings per share. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.3 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Retirement Systems of Alabama increased its holdings in Exelixis by 0.6% in the fourth quarter. Retirement Systems of Alabama now owns 387,465 shares of the biotechnology company’s stock valued at $7,621,000 after purchasing an additional 2,485 shares during the period. Teachers Advisors LLC increased its holdings in Exelixis by 0.7% in the third quarter. Teachers Advisors LLC now owns 347,144 shares of the biotechnology company’s stock valued at $6,151,000 after purchasing an additional 2,577 shares during the period. Vanguard Group Inc increased its holdings in Exelixis by 3.2% in the third quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after purchasing an additional 834,478 shares during the period. Marshall Wace LLP increased its holdings in Exelixis by 109.1% in the third quarter. Marshall Wace LLP now owns 1,627,313 shares of the biotechnology company’s stock valued at $28,836,000 after purchasing an additional 849,096 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Exelixis by 3.2% in the third quarter. Vanguard Group Inc. now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after purchasing an additional 834,478 shares during the period. Institutional investors and hedge funds own 77.22% of the company’s stock.

A number of research analysts have recently commented on the company. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research note on Wednesday. ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a research note on Wednesday. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Piper Jaffray Companies dropped their price target on Exelixis from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 5th. Finally, Oppenheimer set a $40.00 price target on Exelixis and gave the company a “buy” rating in a research note on Thursday, November 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $28.38.

ILLEGAL ACTIVITY NOTICE: “Patrick J. Haley Sells 5,560 Shares of Exelixis, Inc. (EXEL) Stock” was reported by Zolmax and is the property of of Zolmax. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://zolmax.com/investing/patrick-j-haley-sells-5560-shares-of-exelixis-inc-exel-stock/2818217.html.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: How to execute a trade ex-dividend strategy?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Village Farms International  Trading 20.4% Higher
Village Farms International Trading 20.4% Higher
Enablence Technologies  Trading Down 16.7%
Enablence Technologies Trading Down 16.7%
Q4 2019 EPS Estimates for Citizens Financial Group Inc  Lowered by Wedbush
Q4 2019 EPS Estimates for Citizens Financial Group Inc Lowered by Wedbush
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial


Leave a Reply

 
© 2006-2019 Zolmax.